Oncology – PARP inhibitors

Davinderpreet Mangat, Ellie Davenport, and Millie Gray provide a thought leadership piece on PARP inhibitors in various oncology markets. Supporting links: Breast cancer - https://service.datamonitorhealthcare.com/disease/oncology/gynecological-cancer/breast-cancer-hr-her2/disease-analysis/article212246.ece https://service.datamonitorhealthcare.com/disease/oncology/gynecological-cancer/breast-cancer-triple-negative/disease-analysis/article210516.ece Ovarian cancer - https://service.datamonitorhealthcare.com/disease/oncology/gynecological-cancer/ovarian-cancer/disease-analysis/article215125.ece Pancreatic cancer - https://service.datamonitorhealthcare.com/disease/oncology/gastrointestinal-cancer/pancreatic-cancer/market-spotlight/article200459.ece Prostate cancer - https://service.datamonitorhealthcare.com/disease/oncology/urological-cancer/prostate-cancer/disease-analysis/article223558.ece Other platforms: Apple Podcasts -   https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836 Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz TuneIn - https://tunein.com/podcasts/Business--Economics-Podcasts/Pharma-Intelligence-Podcasts-p1140128/ Spotify Podcasts - https://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67